Related Experiment Video
Updated: Jun 1, 2025
Methods for Culturing Human Femur Tissue Explants to Study Breast Cancer Cell Colonization of the Metastatic Niche
Published on: March 15, 2015
Clonal Hematopoiesis in Women With Breast Cancer
Christina Mayerhofer1,2,3, Rachel A Freedman4,5,6, Heather A Parsons3,4,5,6
1Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA.
Insights
Clonal hematopoiesis (CH) is common in breast cancer patients, especially after cytotoxic therapy. However, current evidence does not link CH to breast cancer outcomes, so routine testing is not recommended.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Clonal hematopoiesis (CH) is linked to adverse outcomes like malignancy and cardiovascular disease.
- Emerging research suggests CH may influence outcomes in solid tumors, including breast cancer.
Purpose of the Study:
- To review clinical and biological data on the connection between CH, inflammation, and breast cancer.
- To focus on the prevalence and impact of clonal hematopoiesis of indeterminate potential (CHIP) in breast cancer patients.
Main Methods:
- Summarized data from multiple studies and patient cohorts.
- Assessed CH prevalence in breast cancer patients.
- Examined the relationship between CH and cytotoxic therapy exposure.
- Correlated CH with breast cancer-specific outcomes.
Main Results:
- CH is prevalent in breast cancer patients, particularly those receiving cytotoxic therapies.
- No definitive data currently support an association between CH and breast cancer-specific outcomes.
Conclusions:
- Routine CH testing is not currently supported for breast cancer patients.
- CH presence should not influence breast cancer treatment decisions for most patients.
- Further large-scale, long-term studies are needed to clarify CH implications in breast cancer.
Purpose:
Clonal hematopoiesis (CH) has been associated with a variety of adverse outcomes, most notably hematologic malignancy and ischemic cardiovascular disease. A series of recent studies also suggest that CH may play a role in the outcomes of patients with solid tumors, including breast cancer. Here, we review the clinical and biological data that underlie potential connections between CH, inflammation, and breast cancer, with a focus on the prevalence and impact of clonal hematopoiesis of indeterminate potential in patients with breast cancer.
Methods:
We summarize data from multiple studies, including a series of cohorts of patients with breast cancer, to assess the prevalence of CH, the relationship between CH and exposure to cytotoxic therapy, and the correlation between CH and breast cancer-specific outcomes.
Results:
Our findings indicate that CH is prevalent among patients with breast cancer, particularly those treated with cytotoxic therapies. However, there are no definitive data to support an association between the presence of CH and breast cancer-specific outcomes.
Conclusion:
Current data do not support routine CH testing in patients with breast cancer, nor should the presence of CH influence decisions regarding breast cancer therapy in most patients. However, larger, long-term studies are necessary to further define the implications of CH in patients with breast cancer and guide clinical decision making.
More Related Videos
Related Concept Videos
01:21Hematopoiesis
01:20Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:19Multipotency of Hematopoietic Stem Cells
01:34Production of Formed Elements
Most HSCs commit to...